Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma

Br J Haematol. 2002 Nov;119(2):496-9. doi: 10.1046/j.1365-2141.2002.03826.x.

Abstract

Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3.96-24 g/24 h). On dose reduction or discontinuation, three of these patients showed decreased proteinuria to normal levels (< 1 g/24 h), and proteinuria decreased to 4.5 g/24 h from a peak of 24 g/24 h in one patient. One patient on haemodialysis (hence not evaluable) had proteinuria of 2 g/24 h and elevated creatinine levels. One other patient continued to show elevated creatinine levels (272.8 micro mol/l). Renal biopsies obtained in two patients revealed focal segmental glomerulosclerosis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Bence Jones Protein / urine
  • Creatinine / urine
  • Diphosphonates / adverse effects*
  • Diphosphonates / therapeutic use
  • Drug Administration Schedule
  • Female
  • Humans
  • Kidney Glomerulus / drug effects*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / urine
  • Pamidronate
  • Proteinuria / chemically induced*

Substances

  • Antineoplastic Agents
  • Diphosphonates
  • Bence Jones Protein
  • Creatinine
  • Pamidronate